Moderna said today its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying risk condition.

Preliminary data from an ongoing post-marketing study indicated that the vaccine, mNEXSPIKE, on average, showed greater than a 16-fold increase in neutralizing antibodies against the LP.8.1 variant — currently one of the Sars-CoV-2 variants under monitoring with increasing prevalence globally.

The trial was evaluating safety, tolerability and immunogenicity of the 2025-2026 formula of mNEXSPIKE. The safety profile of the vaccine was consistent with previous studies, the company said.

Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its

See Full Page